Abstract
Introduction
Atherosclerosis is a pathogenic condition of the arterial vessel wall, characterized by lipid deposition, leucocyte infiltration and intimal thickening [1] . [3] [4] [5] [6] [7] [8] in hepatocytes (Fig. 1) . In 1999, bile acids were discovered to function as endogenous ligands for the farnesoid X receptor-␣ (FXR-␣; NR1H4) [9] [10] [11] . Since then several other nuclear receptors (NRs), pregnane-X-receptors (PXR), constitutive androstane receptor (CAR) and the vitamin D receptor (VDR) have been shown to be activated by bile acids [7] .
Inflammation plays a key role in the development of atherosclerosis. Immune cells dominate early atherosclerotic lesions, their effector molecules accelerate progression of the lesions and activation of inflammation can elicit acute coronary syndromes. Atherosclerotic lesions (atheromata) are asymmetric focal thickenings of the innermost layer of the artery, the intima. They consist of cells, connective-tissue elements, lipids and debris. Blood-borne inflammatory and immune cells constitute an important part of an atheroma, the remainder being vascular endothelial and smooth-muscle cells (SMC). In individuals with hyperlipidaemia and signs of systemic inflammation atherosclerosis is initiated by the activation and dysfunction of endothelial cells. Studies in animals and human beings have shown that hypercholesterolemia causes focal activation of endothelium in large-and medium-sized arteries [1]. The infiltration and retention of low-density lipoprotein (LDL) in the arterial intima initiate an inflammatory response in the artery wall. Modification of LDL, through oxidation or enzymatic degradation in the intima, leads to activation of endothelial cells preferentially at sites of hemodynamic strain. Patterns of hemodynamic flow typical for atherosclerosis-prone segments (low average shear but high oscillatory shear stress) cause increased expression of adhesion molecules and inflammatory genes by endothelial cells recruiting blood borne monocytes. Monocytes, which become loaded with cellactivating oxidized LDL (oxLDL) and other lipids, then accumulate in the evolving lesion and transform into foam cells to form early plaques (fatty streaks) in the intima. The relative expression of anti-inflammatory and pro-inflammatory factors will determine whether this early lesions progress into mature atherosclerotic plaques. Cytokines and chemokines-regulated adhesion molecules expressed on endothelial cells and macrophages are essential for recruiting blood-borne macrophages and lymphocytes to the aortic plaques. The vascular cell adhesion molecule (VCAM)-1 binds particularly classes of leucocytes found in the nascent atheroma: the monocyte and the T lymphocyte. The mechanism of VCAM-1 induction early after initiating an atherogenic diet depends on inflammation instigated by modified lipoprotein particles accumulating in the arterial intima in response to the hyperlipidaemia. Constituents of modified lipoprotein particles, among them certain oxidized phospholipids and short-chain aldehydes arising from lipoprotein oxidation, can induce transcriptional activation of the VCAM-1 gene mediated by nuclear factor-B (NF-B) (reviewed in [1]). Pro-inflammatory cytokines such as interleukin (IL)-1␤ or tumour-necrosis factor-␣ (TNF-␣) induce VCAM-1 expression in endothelial cells by this pathway. Human atherosclerotic lesions contain inflammatory cytokines linking hypercholesterolaemia to VCAM-1 expression. A number of genes with potentially
FXR is an adopted member of the metabolic NR superfamily whose expression is mainly restricted to liver, intestine, kidney and adrenals [12] [13] [14] [15] . FXR functions as a bile acids sensor regulating the activity of genes encoding for genes/proteins involved in bile acids synthesis, transport, conjugation and excretion [8] [8] ) (see table in Fig. 1 ).
Molecular biology of FXR
FXR shares the common modular structure of all members of the metabolic-NR superfamily described in Fig. 2 
Fig. 2 Molecular biology of FXR. (A) 3D structure of FXR. (www.rcsb.org/pdb/) in combination with an FXR synthetic agonist GW4064 (B) FXR molecular structure: includes a highly conserved DNA-binding domain in the N-terminal region and a moderately conserved Ligand Binding Domain (LBD) in the C-terminal region. The ligand-independent activation function-1 (AF-1) and ligand-dependent AF-2 are located in the N-terminal and C-terminal regions, respectively. (C) FXR molecular regulation: FXR bind DNA in correspondence to its FXREs. Coactivator and corepressor complexes are involved in FXR activation and repression, respectively. In the absence of a ligand, the FXR heterodimer associates with corepressor complexes, which recruit histonedeacetylase activities. Deacetylation of histone tails leads to chromatin compactation and transcriptional repression. Receptor activation causes the release of the corepressor complex and the AF-2-dependent recruitment of a coactivator complex that contains at least a p160 coactivator (such as SRC-1). These proteins possess histone-acetyltransferase activity that allows chromatin decompactation and gene activation. Multiple protein-protein interactions exist among the FXR and other coactivators such as PRMT-1 (protein arginine(R) methyl transferase-1) and CARM-1 (coactivator-associated arginine methyltransferase-1), inducing histone methylation and PGC-1␣ (ppar-␥ coactivator-1␣) and DRIP-205 (vitamin-D-receptor-interacting protein-205).

Is there a role for FXR in atherosclerosis?
Role of FXR in metabolism [66] . [67, 68] . In cultured hepatocytes, glucose was shown to induce the expression of FXR, whereas insulin counter-regulated this effect [67] . [70] . [67] [68] [69] . [70] and ob/ob [63] mice. [76, 77] . [74] . FXR might also interfere with endothelium-derived nitric oxide activity through modulation of serum asymmetric dimethylarginine (ADMA). ADMA is an endogenous NOS inhibitor [78] and elevated plasma ADMA levels are associated with reduced nitric oxide synthesis in patients with hypercholesterolemia, hypertriglyceridaemia, hypertension, type II diabetes, chronic renal failure and chronic heart failure; reduction of ADMA levels ameliorates nitric oxide synthesis [79] [80] [81] [82] [83] [85] . [86, 87] . [86, 87] . [88] . This receptor plays an antagonistic role in AT1R signalling [89] [90] [91] [92] [93] .
FXR is also involved in the control of hepatic lipogenesis, and its activation reduces the synthesis of FFA and decreases the secretion of VLDL from the liver [62]. The first mechanism identified in the regulation of triglyceride synthesis by FXR ligands (CA and GW4064) is represented by an SHP-mediated inhibition
Fig. 4 Metabolic and vascular effects of FXR. FXR heterodimerizes with RXR. The FXR/RXR heterodimer binds to FXR-responsive elements in the promoters of target genes. Following a ligand-induced activation, FXR induces the expression of genes encoding proteins involved in lipogenesis, lipoprotein clearance and glucose metabolism. In addition, FXR activation and sumoylation in macrophages stabilizes the nuclear co-repressor NCoR on NF-B responsive element inhibiting the expression of inflammatory genes in macrophages, suppresses cell proliferation and migration and increases reverse cholesterol transport in VSMCs and endothelial cells. LDL-R, lowdensity lipoprotein receptor; VLDL, very low-density lipoprotein; IL-1␤, interleukin 1␤; IL-6, interleukin 6; TNF-␣, tumour necrosis factor
Glucose metabolism
Hepatic gluconeogenesis Loss of FXR disrupts normal glucose homeostasis and leads to the development of insulin resistance and hyperglycaemia
Activation of hepatic FXR results in repression of phosphoenoylpyruvate carboxykinase and glucose-6-phosphatase (G6Pase) and increased phosphorylation of GSK3b. Since phosphorylated GSK3b is inactive, the net effect of these activities is an increased level of the dephosphorylated/active glycogen synthase [68, 69]. FXR agonist attenuates the expression of multiple genes involved in neoglucogenesis in wild-type but not in FXRand SHP-deficient mice -thus an FXR-SHP regulatory cascade appears involved in the regulation of gluconeogenesis
Insulin sensitivity FXR deficiency results in impaired insulin signalling and thereby leads to insulin resistance, such changes may result from the elevated free fatty acids noted in the plasma of FXR -/-mice
In vitro experiments had demonstrated that FXR activation improves insulin signalling and insulin-stimulated glucose uptake in differentiated 3T3-L1 cells [71, 72]. The main insulin-responsive glucose transporter is GLUT-4 that plays a critical role in maintaining systemic glucose homeostasis and is subject to complicated metabolic regulation. GLUT-4 expression disorder might cause insulin resistance, and overexpression of GLUT-4 has been confirmed to ameliorate diabetes. Recently it has been demonstrated in adipocytes and hepatocytes cells line that FXR agonist induced GLUT-4 expression [26]. Based on these results, a prediction would be that FXR activation promotes insulin sensitivity, indeed an FXR agonism improves glucose tolerance and insulin sensitivity in db/db, KK-A(y)
Role of FXR vessel wall
Endothelial cells FXR is expressed in several endothelial cell lines such as human aortic endothelial cells, human umbilical vein endothelial cells [73], in rat pulmonary artery endothelial cells (RPAEC) and bovine aortic endothelial cells (BAEC) [74]. Bile acids exert either pro-or -anti-inflammatory activity on endothelial cells. Thus, bile acids increase the expression of intracellular adhesion molecule-1 (ICAM-1) and VCAM-1 via an FXR-independent NF-B and p38 MAPK-dependent mechanism [75]. This pro-attivatory effects of bile acids on ICAM-1 and VCAM-1 was sufficient to promote the adhesion of monocytes to HUVEC, suggesting a contributory role for circulating bile acids to endothelium dysfunction. Because ICAM-1 is abundant in the endothelium, and the induction of ICAM-1 is known to contribute to the leucocyte-induced inflammation in vascular tissues, it is possible that under cholestatic conditions, elevated levels of bile acids in the circulation may cause endothelium dysfunction contributing to the initiation of early events associated with vascular lesions formation. The endothelium plays a crucial role in regulation of vascular tone and changes in the gene expression profile and an altered release of endothelium-derived factors occur in metabolic diseases characterized by an increased production of pro-inflammatory cytokines, decreased secretion of adiponectin from adipose tissue and high circulating levels of free fatty acids and hyperglycaemia
A dysfunctional endothelium displays uncoupling of eNOS accompanied with a decreased generation of nitric oxide and increased expression of endothelin 1 (ET-1). A growing body of evidence suggest that FXR is an important regulatory gene in endothelial cells. Thus, FXR is functional in RPAEC, as demonstrated by induction of its target genes such as SHP after treatment with FXR agonist. Interestingly, activation of FXR in these endothelial cells led to down-regulation of ET-1 expression via negatively interfering with AP-1 signalling [73]. Moreover treatment of BAEC with an FXR ligand up-regulates eNOS mRNA and protein and is associated with an increased production of nitrite/nitrate
Vascular smooth muscle cells Bishop-Bailey et al. [86] have reported that FXR, mRNA and protein, are expressed in atherosclerotic lesions and vascular SMC (VSMC) lines generated from rat aortic (RASMC) and human primary saphenous vein (hSVSMC). The functional roles of FXR in these cell lines are unclear. FXR activation in these cells regulates apoptosis, increases the reverse cholesterol transport from vessel wall to HDL by inducing the expression of PLTP and exerts an antiinflammatory activity by targeting NF-B activation in an SHPdepend manner
FXR ligands also reduce the migration of RASMC and human aortic VSMCs induced by platelet-derived growth factor (PDGF)-␤ [87] VSMCs are important in atherosclerosis because in addition to inflammation they are responsible for an inappropriate vascular remodelling ([reviewed in [1]). The fact that FXR activation down-regulates expression of pro-inflammatory mediators such as iNOS and COX-2 [87], as well as cell migration of VSMCs might have mechanistic relevance in explaining the ability of FXR activation in attenuating vascular inflammation, and remodelling of atherosclerotic plaques
Treatment of RASMC with an FXR ligand increases the expression of type 2 angiotensin receptor (AT2R)
Finally in vitro experiments demonstrated that FXR might interfere in the remodelling of vessels by the up-regulation of the decorin expression in VSMCs [94] . Decorin, a class I small leucine-rich proteoglycans that also includes biglycan, is a component of the extracellular matrix (ECM) of a variety of tissues [95] . Decorin plays a number of important regulatory functions in cell adhesion, migration, proliferation and signalling [96] . Decorin binds to TGF-␤ and PDGF and inhibits their biological activity in a number of cell types [97] [98] [99] [100] [97] [98] [99] [100] . 
Modulation of macrophages-inflammatory response
